Nanosonics Limited

The Business

Nanosonics designs, manufactures and sells trophon, an automated high-level disinfection system for ultrasound probes, alongside its proprietary consumables. The company holds a leading share of the US automated probe disinfection market, built on a razor/blade model: capital equipment sales open the door, then recurring consumable and service revenue compounds for years. CORIS, launched to address endoscope reprocessing, a market Nanosonics estimates at several billion dollars, is the company's attempt to replicate that model in hospital central sterile departments, an environment it has not previously operated in.

Recent Performance

Revenue growth decelerated sharply to 2.7% in FY26, down from 16.8% in FY25, a swing that reflects both a tougher comparison and a reported currency headwind (underlying constant-currency growth ran closer to 6%). Gross margin slipped from 78.2% to 76.9% as US tariffs bit. EBITDA fell to $24.7m from $25.9m. None of this has stopped the shares from trading at $3.11, a level that already prices in a fair amount of optimism about the CORIS opportunity.

Outlook

Revenue growth is expected to reaccelerate over the next three years as CORIS sites scale and the trophon installed base continues to compound. FY27, however, is likely to be the trough year for profitability: EBITDA margin is set to nearly halve as CORIS operating costs ramp ahead of any offsetting revenue, before recovering over the following two years. Earnings are expected to follow the same shape, falling sharply in FY27 before rebounding off a depressed base in FY28 and FY29. The path is one of near-term pain in exchange for a longer-dated payoff that depends heavily on CORIS execution.

Key Risks

The most significant risk is that the current share price already assumes a favourable resolution to several open questions simultaneously, growth, discount rates and CORIS adoption among them, leaving limited room for anything to disappoint. A second risk is CORIS commercial failure: the platform has only a handful of clinical placement sites to date, and Steris, the incumbent in hospital central sterile departments, holds deep existing relationships that CORIS must displace rather than simply out-compete on technology. A third risk relates to the discount rate applied to Nanosonics' cash flows, which is highly sensitive to the interest rate environment; a shift in that rate, in either direction, would materially move how the market and analysts value the business.

What to Watch

The thesis-defining event is Nanosonics' H1 FY27 result in February 2027, which will disclose the CORIS site count and confirm whether the second platform is gaining genuine commercial traction.

• Feb 2027 CORIS site count update — confirms or undermines the multi-platform thesis.
• Q4 2026-Q1 2027 RBA rate decision cycle — the key near-term input into the discount rate debate.
• CY2027 US tariff review — a medical device exemption would ease gross margin pressure.

Latest Developments

FY26 results confirmed the anticipated step-up in CORIS investment, with reported EBITDA falling to $24.7m as commercial spend ahead of CORIS revenue began to show through. Management reaffirmed its phased rollout plan and maintained buyback activity, funded entirely from Nanosonics' net cash position, with no debt on the balance sheet.

Company Description

Nanosonics generates substantially all of its current revenue from the trophon franchise, an automated high-level disinfection system for ultrasound probes sold into hospitals and imaging clinics. The model splits into two components: capital equipment sales, which place new devices into hospitals, and recurring consumables and service revenue, which now makes up 73% of the group total and compounds as the installed base of 39,230 units grows. Nanosonics operates across the Americas, Europe and Asia-Pacific, with the United States its largest and most mature market. Alongside trophon, the company is building CORIS, a second platform targeting automated cleaning in endoscope reprocessing, an adjacent hospital workflow with no existing automated solution.

Where the Growth Is

CORIS is the swing factor in Nanosonics' next decade. It contributed zero revenue in FY26 but is targeted to reach roughly 15% of group revenue by FY36, scaling from a handful of clinical placement sites today to an estimated 250 sites over that period. We place the probability of CORIS achieving genuine commercial traction at around 40%. Failure would not threaten the balance sheet, but it would waste several years of elevated operating spend with no revenue to show for it.

Competitive Position

Nanosonics' advantage rests on installed-base lock-in. Once a hospital places trophon devices across its ultrasound suite, switching to a rival disinfection system means re-training staff, re-validating workflows and re-establishing regulatory compliance, costs most hospitals are reluctant to bear for a consumable that represents a small line item in their budget. The 39,230-unit installed base and the proprietary consumables tied to each device generate the 73% recurring revenue that underpins group profitability, and this position has been stable rather than eroding. We see this moat holding for another five to seven years without material competitive intrusion. CORIS does not yet have this advantage: it must earn trust in a hospital department, central sterile processing, where Nanosonics has no prior track record and where Steris has entrenched relationships.

Management & Capital Discipline

Capital allocation has been disciplined rather than aggressive: buybacks of $20-40m a year, funded entirely from net cash, with zero debt on the balance sheet and no dividend paid to date. Management has phased the CORIS investment deliberately rather than front-loading it, and has been transparent in separating trophon's underlying profitability from the drag CORIS investment creates in the group accounts, an unusual level of disclosure. The honest observation here is that this transparency has not yet been matched by commercial proof: CORIS execution inside hospital central sterile departments, a very different sales motion to point-of-care ultrasound, remains unproven.

Financial Position

Nanosonics carries no debt and holds approximately $155m in net cash, built up over years of trophon cash generation and not yet drawn down materially by the CORIS build-out. That balance alone would fund several years of CORIS operating losses if commercial traction is slower than hoped, without threatening the core business or requiring a capital raise. Free cash flow per share is forecast to trough in FY27 before recovering meaningfully by FY29. On balance sheet strength alone, Nanosonics could comfortably weather a prolonged downturn or a CORIS setback.